Paper29579331
Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial.
Gold KA and 5 others. Cancer, 2018. Cited by 94 papers, by iCite.
Cite this record
ConductScience Library. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial. Papers, record 29579331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29579331
- Disease
- cutaneous squamous cell carcinoma56 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Squamous Cell | Major topic |
| Erlotinib Hydrochloride | Major topic |
| Neoplasm Recurrence, Local | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Skin Neoplasms | Major topic |
| Aged | |
| Aged, 80 and over | |
| Disease Progression | |
| ErbB Receptors | |
| Feasibility Studies | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Response Evaluation Criteria in Solid Tumors |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA016672 | NCI NIH HHS | United States | P30CA016672 | PubMed and NIH | NIH RePORTER |
| R01 CA190628 | NCI NIH HHS | United States | R01CA190628 | PubMed and NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01198028 | Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma | Derived from the trial | Yes |
Source ClinicalTrials.gov
References20
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16014882 | Erlotinib in previously treated non-small-cell lung cancer. | N Engl J Med | 2005 | https://conductscience.org/library/papers/16014882 | PubMed |
| 2 | 25765070 | Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. | Science | 2015 | https://conductscience.org/library/papers/25765070 | PubMed |
| 3 | 27061826 | Anti-programmed cell death-1 therapy in nonmelanoma skin cancer. | Br J Dermatol | 2017 | https://conductscience.org/library/papers/27061826 | PubMed |
| 4 | 4038911 | Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. | Cancer | 1985 | https://conductscience.org/library/papers/4038911 | PubMed |
| 5 | 1698529 | Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. | Cancer | 1990 | https://conductscience.org/library/papers/1698529 | PubMed |
| 6 | 15865067 | Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. | Anticancer Res | 2005 | https://conductscience.org/library/papers/15865067 | PubMed |
| 7 | 27059424 | Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases. | Br J Dermatol | 2016 | https://conductscience.org/library/papers/27059424 | PubMed |
| 8 | 11274625 | Cutaneous squamous-cell carcinoma. | N Engl J Med | 2001 | https://conductscience.org/library/papers/11274625 | PubMed |
| 9 | 16257339 | Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). | Lancet | 2005 | https://conductscience.org/library/papers/16257339 | PubMed |
| 10 | 10025376 | Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. | Am J Clin Oncol | 1999 | https://conductscience.org/library/papers/10025376 | PubMed |
| 11 | 25303977 | Mutational landscape of aggressive cutaneous squamous cell carcinoma. | Clin Cancer Res | 2014 | https://conductscience.org/library/papers/25303977 | PubMed |
| 12 | 18784157 | Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance? | Oncologist | 2008 | https://conductscience.org/library/papers/18784157 | PubMed |
| 13 | 21810686 | Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/21810686 | PubMed |
| 14 | 28964539 | Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial. | J Am Acad Dermatol | 2017 | https://conductscience.org/library/papers/28964539 | PubMed |
| 15 | 19097774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 16 | 25409260 | Genetic basis for clinical response to CTLA-4 blockade in melanoma. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25409260 | PubMed |
| 17 | 15681519 | Mortality risk from squamous cell skin cancer. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/15681519 | PubMed |
| 18 | 22261807 | A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22261807 | PubMed |
| 19 | 23375456 | Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. | J Am Acad Dermatol | 2013 | https://conductscience.org/library/papers/23375456 | PubMed |
| 20 | 20231499 | Incidence estimate of nonmelanoma skin cancer in the United States, 2006. | Arch Dermatol | 2010 | https://conductscience.org/library/papers/20231499 | PubMed |
Cited by54
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 94 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41458609 | Mechanism of action of Butein in cutaneous squamous cell carcinoma through regulation of the TWEAK-FN14 signaling pathway. | Front Oncol | 2025 | https://conductscience.org/library/papers/41458609 | PubMed |
| 41228268 | Cutaneous Squamous Cell Carcinoma in Immunocompromised Patients. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41228268 | PubMed |
| 40632444 | The Role of Cetuximab in Non-Melanoma Skin Cancer: A Review of Clinical Evidence and Emerging Strategies. | Curr Treat Options Oncol | 2025 | https://conductscience.org/library/papers/40632444 | PubMed |
| 40405694 | Cetuximab plus 5-fluorouracil in patients with advanced cutaneous squamous cell carcinoma: a retrospective cohort study. | J Dtsch Dermatol Ges | 2025 | https://conductscience.org/library/papers/40405694 | PubMed |
| 40110500 | The Role of Radiosensitizing Drugs in Osteosarcoma Treatment: Mechanisms and Clinical Perspectives. | Drug Des Devel Ther | 2025 | https://conductscience.org/library/papers/40110500 | PubMed |
| 39582977 | KS-cSCC-1 and KS-cSCC-2: two novel cutaneous squamous cell carcinoma cell lines established from Japanese patients. | Front Med (Lausanne) | 2024 | https://conductscience.org/library/papers/39582977 | PubMed |
| 39199674 | The Mutational and Microenvironmental Landscape of Cutaneous Squamous Cell Carcinoma: A Review. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39199674 | PubMed |
| 39050978 | Real-World Treatment Patterns and Outcomes of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma Treated in US Oncology Practices. | Cancer Manag Res | 2024 | https://conductscience.org/library/papers/39050978 | PubMed |
| 39000164 | Therapeutic Approaches for Non-Melanoma Skin Cancer: Standard of Care and Emerging Modalities. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39000164 | PubMed |
| 38954315 | Systemic Therapy for Non-Melanoma Skin Cancers: Latest Advances. | Curr Oncol Rep | 2024 | https://conductscience.org/library/papers/38954315 | PubMed |
| 38929802 | The Immunomodulatory Potential of Concurrent High-Dose Radiotherapy and Immune Checkpoint Inhibitor Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Initial Results. | J Pers Med | 2024 | https://conductscience.org/library/papers/38929802 | PubMed |
| 38791879 | Cutaneous Squamous Cell Carcinoma: An Updated Review. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38791879 | PubMed |
| 38655092 | Molecular targeted therapies for cutaneous squamous cell carcinoma: recent developments and clinical implications. | EXCLI J | 2024 | https://conductscience.org/library/papers/38655092 | PubMed |
| 38471711 | High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma. | J Immunother Cancer | 2024 | https://conductscience.org/library/papers/38471711 | PubMed |
| 37848259 | Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma. | J Immunother Cancer | 2023 | https://conductscience.org/library/papers/37848259 | PubMed |
| 37417890 | Effectiveness and toxicity of cetuximab with concurrent RT in locally advanced cutaneous squamous cell skin cancer: a case series. | Oncotarget | 2023 | https://conductscience.org/library/papers/37417890 | PubMed |
| 37235052 | Targeting receptor tyrosine kinase signaling: Avenues in the management of cutaneous squamous cell carcinoma. | iScience | 2023 | https://conductscience.org/library/papers/37235052 | PubMed |
| 35954316 | Advances in Cutaneous Squamous Cell Carcinoma Management. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35954316 | PubMed |
| 35620707 | Sequencing of Cutaneous Squamous Cell Carcinoma Primary Tumors and Patient-Matched Metastases Reveals ALK as a Potential Driver in Metastases and Low Mutational Concordance in Immunocompromised Patients. | JID Innov | 2022 | https://conductscience.org/library/papers/35620707 | PubMed |
| 35454779 | Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: The Current and Future Role of Radiation Therapy in the Era of Immunotherapy. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35454779 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| ERLOTINIB | CHEMBL553 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL553 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29579331
GET https://conductscience.org/api/papers/v1/29579331/cited_by?page=2